The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
ThermoFisher Scientific Patheon Pharma Services
×
Recent searches Clear History
Suggestions
All Results
 Search
 US | EN

Early decisions, late-stage consequences: How the “3S” determine development success

When not addressed early, solubility, stability, and scalability (3S) challenges can delay program timelines, increase costs, and introduce CMC regulatory risks.

Solubility, Stability, and Scalability (3S) are critical pillars of successful drug product CMC and commercial launch—yet shortcuts in early development can be costly to address later.

Poor solubility can limit oral bioavailability and require high pill burdens; inadequate stability can compromise product performance, increase packaging costs, and shorten shelf life; and scalability challenges can lead to process validation risks, manufacturing delays, or costly redevelopment as products approach registration and launch.

In this on-demand webinar, Thermo Fisher’s experts discuss how integrating “3S” thinking into the earliest stages of drug development creates a strong foundation for clinical and commercial success. Because solubility, stability, and scalability are closely interconnected, a holistic development strategy that balances each is essential.

Real-world insights from CDMO development programs

Real case studies from an extensive portfolio of development challenges illustrate the tangible benefits of a proactive 3S-led approach. Our experts also highlight how the depth and breadth of an innovative CDMO partner can help integrate technical solutions to anticipate risk, streamline scale-up, and accelerate development.

What you’ll learn by watching this webinar:

  • Understand the interconnection between solubility, stability, and scalability
  • Learn how 3S integration reduces drug product technical, regulatory, and supply risks
  • Discover how scientific depth and cross-functional expertise support scale-up